Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Humana ( (HUM) ) just unveiled an announcement.
In September 2025, Humana Inc.’s senior management will meet with investors and analysts to reaffirm its earnings guidance for the fiscal year ending December 31, 2025. The company projects approximately $13.77 in diluted earnings per share and $17.00 in adjusted earnings per share, consistent with previous guidance. Humana emphasizes the use of adjusted EPS as a comprehensive measure for evaluating its core operating performance, aiding in planning and decision-making.
The most recent analyst rating on (HUM) stock is a Buy with a $325.00 price target. To see the full list of analyst forecasts on Humana stock, see the HUM Stock Forecast page.
Spark’s Take on HUM Stock
According to Spark, TipRanks’ AI Analyst, HUM is a Outperform.
Humana’s overall stock score reflects strong financial performance and a positive earnings outlook, supported by strategic initiatives like Medicaid expansion and CenterWell Pharmacy’s growth. Technical indicators show bullish momentum, though caution is advised due to overbought signals. Valuation is fair, and the new credit agreement enhances financial flexibility. However, challenges in the home health segment and ongoing litigation present risks.
To see Spark’s full report on HUM stock, click here.
More about Humana
Humana Inc. operates in the healthcare industry, providing health insurance and related services, with a focus on Medicare Advantage plans.
Average Trading Volume: 1,677,281
Technical Sentiment Signal: Sell
Current Market Cap: $35.83B
Learn more about HUM stock on TipRanks’ Stock Analysis page.